|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2005-5-3
|
|
pubmed:abstractText |
Intensification therapy adding a boosted protease inhibitor (PI) to a failing regimen has the potential to worsen the resistance profile. Sixty-six patients included in four different boosted PI intensification studies were assessed and resistance mutations in the reverse transcriptase and protease genes were evaluated at baseline and 4 weeks after the initiation of the intensification strategy. Only one of the 66 patients developed changes in their pattern of mutations able to generate or increase resistance to new drugs.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Carbamates,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Protease,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Protease Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/HIV Reverse Transcriptase,
http://linkedlifedata.com/resource/pubmed/chemical/Indinavir,
http://linkedlifedata.com/resource/pubmed/chemical/Lopinavir,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrimidinones,
http://linkedlifedata.com/resource/pubmed/chemical/Ritonavir,
http://linkedlifedata.com/resource/pubmed/chemical/Saquinavir,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides,
http://linkedlifedata.com/resource/pubmed/chemical/amprenavir
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0269-9370
|
|
pubmed:author |
pubmed-author:ArnedoMireiaM,
pubmed-author:BigliaM AlejandraMA,
pubmed-author:BlancoJosé LJL,
pubmed-author:GarcíaFelipeF,
pubmed-author:GatellJosé MJM,
pubmed-author:LagunoMontserratM,
pubmed-author:LarrousseMariaM,
pubmed-author:LeonAgatheA,
pubmed-author:LoncaMontserratM,
pubmed-author:MallolasJosepJ,
pubmed-author:MartínezEstebanE,
pubmed-author:MilinkovicAnaA,
pubmed-author:MiróJosé MJM,
pubmed-author:PumarolaTomásT
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
19
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
829-31
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15867498-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:15867498-Carbamates,
pubmed-meshheading:15867498-Drug Resistance, Multiple, Viral,
pubmed-meshheading:15867498-Follow-Up Studies,
pubmed-meshheading:15867498-HIV Infections,
pubmed-meshheading:15867498-HIV Protease,
pubmed-meshheading:15867498-HIV Protease Inhibitors,
pubmed-meshheading:15867498-HIV Reverse Transcriptase,
pubmed-meshheading:15867498-HIV-1,
pubmed-meshheading:15867498-Humans,
pubmed-meshheading:15867498-Indinavir,
pubmed-meshheading:15867498-Lopinavir,
pubmed-meshheading:15867498-Mutation,
pubmed-meshheading:15867498-Pyrimidinones,
pubmed-meshheading:15867498-Ritonavir,
pubmed-meshheading:15867498-Saquinavir,
pubmed-meshheading:15867498-Sulfonamides,
pubmed-meshheading:15867498-Treatment Failure,
pubmed-meshheading:15867498-Viral Load
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.
|
|
pubmed:affiliation |
Infectious Diseases Service, IDIBAPS, Hospital Clínic, Faculty of Medicine, University of Barcelona, Barcelona, Spain.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
